Vyndaqel Global Market Report 2026

Vyndaqel, known as tafamidis, is a medication used to manage transthyretin amyloid cardiomyopathy (ATTR-CM), a heart disorder caused by the accumulation of misfolded transthyretin proteins. It works by stabilizing the transthyretin protein, preventing it from misfolding and building up in the heart. Vyndaqel is prescribed to lower the risk of cardiovascular-related deaths and hospitalizations in patients with ATTR-CM. It is also used to enhance the quality of life for those affected by this progressive and often fatal condition.

The main product types of Vyndaqel are Vyndaqel (tafamidis 20 mg) and Vyndamax (tafamidis 61 mg). Vyndaqel (Tafamidis 20 mg) is a transthyretin stabilizer used to manage transthyretin amyloid polyneuropathy (ATTR-PN) by slowing the progression of the disease. It is indicated for familial amyloid polyneuropathy (FAP) and wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) and is available through hospital pharmacies, online pharmacies, and retail pharmacies.

Tariffs have affected the Vyndaqel market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and formulation excipients used in transthyretin stabilizer therapies. These impacts have been most pronounced in branded rare cardiac drug segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have experienced pricing pressures due to trade dependencies. However, tariffs have encouraged localized formulation and packaging, supporting supply continuity and cost stability.

The vyndaqel market research report is one of a series of new reports from The Business Research Company that provides vyndaqel market statistics, including vyndaqel industry global market size, regional shares, competitors with a vyndaqel market share, detailed vyndaqel market segments, market trends and opportunities, and any further data you may need to thrive in the vyndaqel industry. This vyndaqel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vyndaqel market size has grown rapidly in recent years. It will grow from $1.9 billion in 2025 to $2.23 billion in 2026 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to approval of tafamidis, lack of effective attr-cm treatments, improved cardiac imaging diagnostics, growth of rare disease programs, increasing cardiology referrals.

The vyndaqel market size is expected to see rapid growth in the next few years. It will grow to $4.19 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to aging population growth, rising awareness of amyloid cardiomyopathy, expansion of specialty cardiology centers, increased genetic testing adoption, growing reimbursement support. Major trends in the forecast period include increasing adoption of transthyretin stabilizers, rising diagnosis of attr cardiomyopathy, expansion of oral therapies for rare cardiac diseases, growing focus on disease-modifying cardiac drugs, increased use of long-term amyloidosis treatment.

The increasing adoption of precision medicine is expected to drive the expansion of the Vyndaqel market in the coming years. Precision medicine focuses on customizing medical treatment for individual patients based on their genetic, environmental, and lifestyle factors, enhancing the effectiveness and outcomes of therapies. Its adoption is rising as more patients and healthcare providers prefer personalized treatments that provide targeted care and improved management of chronic conditions. Vyndaqel supports precision medicine by delivering targeted therapy for transthyretin amyloidosis (ATTR), ensuring that patients most likely to benefit receive the treatment. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six approvals in 2022. Consequently, the growing adoption of precision medicine is fueling the growth of the Vyndaqel market.

The increasing healthcare expenditure is expected to drive the growth of the Vyndaqel market in the coming years. Healthcare expenditure refers to the total financial resources allocated to medical goods and services aimed at maintaining and improving population health. Healthcare spending is rising as an aging population demands more frequent medical attention and long-term healthcare services. Higher healthcare expenditure facilitates broader access to Vyndaqel by providing greater funding for high-cost therapies and enhancing the diagnostic and care infrastructure necessary for managing transthyretin amyloid cardiomyopathy. For example, in April 2025, according to the Office for National Statistics, a UK-based government department, total healthcare spending increased by 6.5% in nominal terms between 2023 and 2024, and by 2.4% in real terms after adjusting for inflation. Consequently, the rising healthcare expenditure is fueling the growth of the Vyndaqel market.

Major companies operating in the Vyndaqel segment are concentrating on expanding their production facilities to manufacture active pharmaceutical ingredients, including transthyretin-stabilizing therapeutics, aimed at improving cardiovascular outcomes and lowering hospitalization rates in patients with ATTR-CM. Transthyretin-stabilizing therapeutics are pharmacological agents designed to bind and stabilize transthyretin (TTR) tetramers, preventing their breakdown into misfolded monomers that aggregate and form amyloid deposits. For example, in November 2024, BridgeBio Pharma, a US-based biopharmaceutical company specializing in genetic diseases, introduced Attruby (acoramidis), a near-complete (>=90%) transthyretin (TTR) stabilizer developed to tackle key challenges in transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby (acoramidis) binds and stabilizes TTR tetramers, preventing their dissociation into misfolded monomers that accumulate as amyloid deposits in cardiac tissue. This therapy provides significant cardiovascular advantages, including reductions in cardiovascular death and hospitalizations related to cardiovascular issues, while maintaining TTR's native physiological functions, making it an effective option for enhancing patient outcomes and managing ATTR-CM.

Major companies operating in the vyndaqel market are Pfizer Inc.

North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vyndaqel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vyndaqel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vyndaqel market consists of sales of cardiovascular medications, neuropathy medications, anticoagulants and diuretics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vyndaqel Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses vyndaqel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vyndaqel ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vyndaqel market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Vyndaqel (Tafamidis 20 mg); Vyndamax (Tafamidis 61 mg)
• 2) By Disease Type: Familial Amyloid Polyneuropathy (FAP); Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules; Once-Daily Dosing Regimen; Chronic Long-Term Therapy Use
• 2) By Vyndamax (Tafamidis 61 mg): Oral Capsules; Once-Daily Dosing Regimen; Chronic Long-Term Therapy Use
• Companies Mentioned: Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.